Neurogene Entered into a Definitive Merger Agreement with Neoleukin to Advance Differentiated Genetic Therapies Pipeline
- The combined company is expected to have ~$200M in cash or cash equivalents incl. ~$95M from concurrent private financing by Neurogene’s new and existing investors. The merger is expected to close in Q4’23
- The combined company focuses on advancing Neurogene’s pipeline of differentiated genetic medicines, incl. NGN-401 for Rett syndrome which uses novel gene regulation technology
- Neurogene’s clinical-stage portfolio also includes NGN-101, which is currently being evaluated in a P-I/II clinical trial in children with CLN5 Batten disease. The combined company is expected to operate under the name Neurogene Inc. and will trade on the Nasdaq under the ticker symbol “NGNE”
Ref: Globenewswire | Image: Neurogene
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
